Intellia Therapeutics (NTLA) News Today $26.50 +0.08 (+0.30%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 10:41 AM | ca.finance.yahoo.comApple Maps launches on the web to challenge Google MapsJuly 24 at 4:01 PM | globenewswire.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 23, 2024 | investorplace.com7 Biotech Stocks to Keep on Your Clinical RadarJuly 22, 2024 | americanbankingnews.comEquities Analysts Set Expectations for Intellia Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:NTLA)July 19, 2024 | finance.yahoo.comWe're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn RateJuly 17, 2024 | investorplace.com3 Gene Editing Stocks That Could Grow Your WealthJuly 17, 2024 | investorplace.com3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July EditionJuly 17, 2024 | americanbankingnews.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $69.00 Consensus Target Price from AnalystsJuly 16, 2024 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by BNP Paribas Financial MarketsBNP Paribas Financial Markets cut its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 64.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 74,515 shares ofJuly 14, 2024 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fourteen research firms that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and ten have issuedJuly 11, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 9.3%Intellia Therapeutics (NASDAQ:NTLA) Trading Up 9.3%July 10, 2024 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Chevy Chase Trust Holdings LLCChevy Chase Trust Holdings LLC raised its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 8.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,074,610 sJuly 9, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Down 4.6%Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 4.6%July 9, 2024 | investorplace.comThe 3 Most Undervalued Gene Editing Stocks to Buy in July 2024July 9, 2024 | fool.comThe Bull Case for Intellia Therapeutics Stock Just Got Even StrongerJuly 8, 2024 | investorplace.com3 Pharma Stocks Already Ushering in the Next Biotech BoomJuly 5, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in July 2024July 5, 2024 | marketbeat.comSumitomo Mitsui Trust Holdings Inc. Reduces Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Sumitomo Mitsui Trust Holdings Inc. trimmed its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 2.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,399,318 shareJuly 2, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 3.8% Intellia Therapeutics (NASDAQ:NTLA) Shares Down 3.8%July 2, 2024 | prnewswire.comKuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law FirmJuly 1, 2024 | marketbeat.comVanguard Group Inc. Increases Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Vanguard Group Inc. boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,347,449 shares of the company's stock after purchasing an additional 155,579 shares dJune 28, 2024 | investorplace.comTreasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered YetJune 27, 2024 | investorplace.comYou've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.June 27, 2024 | marketbeat.comIntellia Therapeutics' (NTLA) "Buy" Rating Reaffirmed at Canaccord Genuity GroupCanaccord Genuity Group reissued a "buy" rating and issued a $73.00 price objective on shares of Intellia Therapeutics in a research report on Thursday.June 27, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Upgraded to "Sell" at StockNews.comStockNews.com upgraded Intellia Therapeutics to a "sell" rating in a report on Thursday.June 26, 2024 | investorplace.comRags to Riches: 3 Gene Editing Stocks That Could Make Early Investors RichJune 26, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Down 7.2%Intellia Therapeutics (NASDAQ:NTLA) Trading Down 7.2%June 26, 2024 | globenewswire.comIntellia Therapeutics Announces CFO TransitionJune 25, 2024 | globenewswire.comIntellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery PlatformJune 24, 2024 | marketbeat.comCantor Fitzgerald Reaffirms "Overweight" Rating for Intellia Therapeutics (NASDAQ:NTLA)Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price target on shares of Intellia Therapeutics in a report on Monday.June 24, 2024 | benzinga.com5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And MoreJune 22, 2024 | marketbeat.comWellington Management Group LLP Decreases Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Wellington Management Group LLP lessened its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 7.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,456,917 shares of the compaJune 21, 2024 | investorplace.comWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024June 19, 2024 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation anJune 18, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Intellia Therapeutics in a report on Tuesday.June 17, 2024 | globenewswire.comIntellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024June 17, 2024 | marketbeat.comZacks Research Analysts Boost Earnings Estimates for Intellia Therapeutics, Inc. (NASDAQ:NTLA)Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Equities researchers at Zacks Research boosted their FY2024 earnings per share (EPS) estimates for Intellia Therapeutics in a research note issued on Thursday, June 13th. Zacks Research analyst R. Department now anticipates that the companJune 15, 2024 | marketbeat.comOpaleye Management Inc. Buys New Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Opaleye Management Inc. bought a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 99,000 shares of the company's stock, valued at approximately $3,019,000. Intellia Therapeutics aJune 14, 2024 | globenewswire.comIntellia Therapeutics Names Brian Goff to its Board of DirectorsJune 12, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Up 10.3%Intellia Therapeutics (NASDAQ:NTLA) Trading Up 10.3%June 11, 2024 | marketbeat.comAvidity Partners Management LP Boosts Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Avidity Partners Management LP grew its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 18.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 447,434 shares of the company's stock after acquiringJune 9, 2024 | fool.comCathie Wood Goes Bargain Hunting: 2 Stocks She Just BoughtJune 8, 2024 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Seven Eight Capital LPSeven Eight Capital LP lifted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 219.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 61,192 shares of the company's stock after purchasing anJune 8, 2024 | fool.comThese 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right NowJune 7, 2024 | marketbeat.comSectoral Asset Management Inc. Cuts Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Sectoral Asset Management Inc. lowered its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 91.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,300 shares of the company's stock aftJune 6, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtJune 5, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in June 2024June 5, 2024 | marketbeat.comRafferty Asset Management LLC Purchases 77,873 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Rafferty Asset Management LLC lifted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 31.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 328,998 shares of the compJune 5, 2024 | seekingalpha.comIntellia Therapeutics Presents Promising In Vivo CRISPR ResultsJune 4, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday. Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Heard about the 72-Hour Profit Surge? Read this… (Ad)One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge… Click here now to get all the details. NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.770.62▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼84▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Editas Medicine News Cellectis News Sangamo Therapeutics News CRISPR Therapeutics News Lantheus News Neogen News Celldex Therapeutics News Myriad Genetics News QuidelOrtho News Achieve Life Sciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NTLA Stock Alerts